Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Merck gives up on COVID-19 vaccine candidates

By Chris Newmarker | January 25, 2021

Merck logoMerck (NYSE:MRK) announced today that it is discontinuing the development of its two COVID-19 vaccine candidates, with the Kenilworth, N.J.-based pharma company focusing on two therapeutic candidates instead.

Merck officials say they made the decision after Phase 1 clinical studies that showed the V590 and V591 vaccine candidates produced an immune response that was inferior to a natural infection, as well as what has been reported for other COVID-19 vaccines. The company plans to record a charge in its Q4 2020 results related to the discontinuation.

“We are grateful to our collaborators who worked with us on these vaccine candidates and to the volunteers in the trials,” said Dr. Dean Y. Li, president of Merck Research Laboratories.

“We are resolute in our commitment to contribute to the global effort to relieve the burden of this pandemic on patients, health care systems and communities,” Li said in a news release.

Merck will continue research related to , as well as development and production involving to two therapeutic candidates:

  • MK-7110 (formerly CD24Fc) is an investigational recombinant fusion protein that modulates the inflammatory response to SARS-CoV-2, principally by targeting a novel immune pathway checkpoint. Interim Phase 3 study results showed MK-7110 more than halving the risk of death or respiratory failure in patients hospitalized with moderate to severe COVID-19. Merck expects full study results in Q1 2021. The U.S. government has agreed to pay Merck roughly $356 million for 60,000–100,000 doses of MK-7110 through June 30, 2021.
  • Molnupiravir (MK-4482) is an oral novel investigational antiviral agent that Merck is developing in collaboration with Ridgeback Bio. Molnupiravir is currently being evaluated in Phase 2/3 clinical trials in both the hospital and outpatient settings, with the study expected to be primarily completed in 2021. The drug has shown promise in ferrets.

Filed Under: Drug Discovery and Development, Infectious Disease
Tagged With: coronavirus, covid-19, COVID-19 vaccine, Merck
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Pfizer-BioNTech vaccine
U.S. government plans to stop paying for COVID-19 vaccines 
Monkeypox
U.S. to boost supplies of Tpoxx to fight monkeypox outbreak
Pfizer-BioNTech
Next-gen Pfizer-BioNTech vaccine candidates fare well in Phase 2/3 study
covid-19 vaccine
Fall 2022 COVID-19 vaccine candidate tracker

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50